Physician profile
Ramez W Samuel
NPI 1447303417
$4,934.68
in general payments reported to CMS, 2019-2025
41 companies · $752 in 2025
The $752 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $547 · 2021: $1,038 · 2022: $860 · 2023: $654 · 2024: $559 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $591.93 | 2020-2025 | Farxiga, Breztri, Lokelma |
| Lilly USA, LLC | $523.12 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $514.58 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $451.17 | 2019-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $292.86 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.49 | 2020-2025 | Xifaxan, Relistor |
| Gilead Sciences, INC. | $177.29 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.21 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $168.76 | 2022-2024 | Verquvo, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $146.79 | 2019-2024 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $122.07 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $113.53 | 2019-2025 | Invega Sustenna, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.91 | 2020-2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $105.82 | 2019-2021 | |
| Abbott Laboratories | $103.77 | 2021-2025 | Freestyle Libre 3 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $94.65 | 2020-2023 | Afrezza |
| Vanda Pharmaceuticals INC. | $92.71 | 2022-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $81.20 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Janssen Biotech, INC. | $78.47 | 2022-2025 | Symtuza, Tremfya |
| Amgen INC. | $73.55 | 2019-2023 | Repatha, Otezla |
| Scilex Pharmaceuticals INC. | $68.33 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.08 | 2025 | Caplyta |
| Amarin Pharma, INC. | $57.45 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $53.93 | 2022-2023 | Seglentis |
| Exact Sciences Corporation | $51.84 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $45.30 | 2021-2024 | |
| Dexcom, INC. | $39.84 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $33.79 | 2021 | |
| Neurelis, INC. | $32.02 | 2022-2023 | Valtoco |
| Neurocrine Biosciences, INC. | $31.21 | 2024-2025 | Ingrezza |
| Insulet Corporation | $31.07 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $29.25 | 2023 | Gvoke Hypopen |
| Abbvie INC. | $28.61 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.72 | 2019 | |
| Evoke Pharma, INC. | $26.90 | 2022 | |
| Arbor Pharmaceuticals, INC. | $22.61 | 2019 | |
| Renalytix Ai, INC. | $22.45 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Lundbeck LLC | $16.15 | 2024 | Rexulti |
| Azurity Pharmaceuticals, INC. | $14.96 | 2024 | Horizant |
| Becton, Dickinson and Company | $12.79 | 2019 | |
| Horizon Therapeutics Plc | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramez Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.